research

First Opinion Amy West

ACL tears in women: Too many injuries and too little research

Adam's Biotech Scorecard Adam Feuerstein

STAT Plus: On Andrew Left and the government’s fraud case

The Readout Elaine Chen

STAT Plus: venBio raises $528 million for its fifth fund

In the Lab Angus Chen

STAT Plus: With Biden’s departure in sight, advocates seek to preserve gains of Cancer Moonshot

Morning Rounds Theresa Gaffney

Morning Rounds: Grindr gets into health care lobbying

The Readout Elaine Chen

STAT Plus: The debate over how long to use Alzheimer’s drugs

A STAT Investigation Katherine Eban

Mount Sinai mounted aggressive campaign to stifle debate over revelations about its controversial brain research

The Readout Elaine Chen

STAT Plus: Testing GLP-1s in Alzheimer’s, and is Medicare a good negotiator?

Health Theresa Gaffney

There’s more data for trans people with HIV than any other disease — but it’s still flawed

In the Lab Alia Sajani

STAT Plus: Parasite engineered to treat brain development disorder in mice shows potential in study

Health Elizabeth Cooney

New cardiovascular risk model could greatly decrease use of statins and increase heart attacks, study warns

The Readout Meghana Keshavan

STAT Plus: The biotech news you need from the weekend

The Readout Elaine Chen

STAT Plus: The worst for Dexcom may not be over

Politics Rohan Rajeev

STAT Plus: Kamala Harris’ views on health care were shaped by her mother, cancer researcher Shyamala Gopalan

Health Angus Chen

Breast cancer study reveals a paradox of mastectomy

Adam's Biotech Scorecard Adam Feuerstein

STAT Plus: A preview of Neurocrine’s muscarinic drug readout

The Readout Meghana Keshavan

STAT Plus: A potential rival for Wegovy and Zepbound enters the fray

The Readout Elaine Chen

STAT Plus: Merck lays off workers amid rough pharma job market

The Readout Elaine Chen

STAT Plus: Contradictory coverage decisions in North Carolina

The Readout Meghana Keshavan

STAT Plus: Four health care and biotech updates to stay on top of this week

First Opinion Oni Blackstock and Whitney C. Irie

The newest tool to prevent STIs is not available to everyone: A call for participatory and inclusive research

The Readout Meghana Keshavan

STAT Plus: Novo, Lilly shares sink due to concerns over competition

First Opinion David Gillum, Rebecca Moritz, and Gregory D. Koblentz

The ‘Risky Research Review Act’ would do more harm than good

In the Lab Jonathan Wosen

Massive study of veterans’ DNA shows how diversity can help researchers decipher the genome

Politics Nicholas Florko

STAT Plus: ‘Legal’ psychedelic mushrooms actually contain illegal hallucinogens, study shows

Adam's Biotech Scorecard Adam Feuerstein

STAT Plus: Novartis not ready to admit a $3 billion mistake

The Readout Elaine Chen

STAT Plus: The biotech news stories you need to know today

Exclusive Megan Molteni

STAT Plus: Broad Institute, facing end of Microsoft cloud contract, shuffles data science leadership

First Opinion Spencer Phillips Hey and Michael S. Wilkes

IRBs fail to assess trials’ scientific merit, putting participants at risk